Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Harvard Business School
Baxter
Dow
McKinsey

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RISPERIDONE

See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for RISPERIDONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Indication NCT01770600 Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression Withdrawn University of Alabama at Birmingham N/A 2010-04-01 This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for RISPERIDONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000267 Risperidone Treatment in Dually-Diagnosed Individuals - 2 Completed New York State Psychiatric Institute Phase 2 1969-12-31 The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000267 Risperidone Treatment in Dually-Diagnosed Individuals - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 1969-12-31 The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000272 New Approaches to Cocaine Abuse Medications (B) - 7 Completed New York State Psychiatric Institute Phase 2 1995-03-01 The purpose of this study is to measure the effect of risperidone in cocaine abusers.
NCT00000272 New Approaches to Cocaine Abuse Medications (B) - 7 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-03-01 The purpose of this study is to measure the effect of risperidone in cocaine abusers.
NCT00000309 Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1 Terminated National Institute on Drug Abuse (NIDA) Phase 2 1994-08-01 The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RISPERIDONE

Condition Name

Condition Name for RISPERIDONE
Intervention Trials
Schizophrenia 281
Schizoaffective Disorder 61
Bipolar Disorder 45
Psychotic Disorders 40
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for RISPERIDONE
Intervention Trials
Schizophrenia 302
Psychotic Disorders 120
Disease 105
Mental Disorders 68
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for RISPERIDONE

Trials by Country

Trials by Country for RISPERIDONE
Location Trials
United States 972
China 52
Canada 47
Spain 40
Italy 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for RISPERIDONE
Location Trials
California 87
New York 75
Texas 56
Ohio 51
Florida 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for RISPERIDONE

Clinical Trial Phase

Clinical Trial Phase for RISPERIDONE
Clinical Trial Phase Trials
Phase 4 176
Phase 3 121
Phase 2/Phase 3 7
[disabled in preview] 74
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for RISPERIDONE
Clinical Trial Phase Trials
Completed 340
Terminated 41
Unknown status 36
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for RISPERIDONE

Sponsor Name

Sponsor Name for RISPERIDONE
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 47
Janssen, LP 38
National Institute of Mental Health (NIMH) 35
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for RISPERIDONE
Sponsor Trials
Other 442
Industry 324
NIH 55
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Moodys
AstraZeneca
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.